Acumen, JCR partner to enhance Alzheimer’s therapy delivery
The partnership combines Acumen's expertise in amyloid beta oligomer-selective antibodies with JCR's blood-brain barrier-penetrating technology, to improve AD treatment delivery.
Bayer gets FDA approval for finerenone to treat heart failure with LVEF
ViiV Healthcare expands MPP licensing deal for long-acting HIV treatment
RayzeBio’s new hub revolutionizes cancer treatment with next-gen RPTs
Imugene’s azer-cel shows promise in treating relapsed DLBCL
Elegen, Nutcracker unveil cell-free RNA manufacturing pilot
Analysis
View MoreThe ultimate hub for fine and speciality chemicals
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery